While AGTR2 has been classically involved in antagonizing AGTR1-mediated actions, a recent study has demonstrated that the dual targeting of AGTR1 and AGTR2 using losartan and CGP42112A synergistically decreases cell survival and angiogenesis in epithelial ovarian cancer, through the inhibition of PLC β3 phosphorylation and VEGF expression [138]. This evidence concerns the gene AGTR2 and ovarian carcinoma.